Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha 2 gene therapy - Genenta Science

Next Previous
Drug Profile

Interferon alpha 2 gene therapy - Genenta Science

Alternative Names: Autologous CD34+ enriched HSPCs expressing interferon-alpha 2 - Genenta Science; Genetically modified HSPCs - Genenta Science; Temferon; Temferon_GBM; Temferon_MM

Latest Information Update: 12 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genenta Science
  • Developer AGC Biologics; Genenta Science
  • Class Antineoplastics; Gene therapies; Haematopoietic stem cells therapies; Immunotherapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Multiple myeloma; Renal cell carcinoma
  • Preclinical Bladder cancer; Haematological malignancies; Solid tumours
  • Research Breast cancer; Colorectal cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 04 Dec 2024 Phase-I/II clinical trials in Renal cell carcinoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Italy (Parenteral) (NCT06716853)
  • 02 Oct 2024 Agenzia Italiana del Farmaco (AIFA) approves IND application for Temferon™ in Renal cell carcinoma
  • 02 Oct 2024 Genenta Science plans a phase I trial for Renal cell carcinoma (Metastatic disease) (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top